Background
Blastocystis sp. is a common protozoan intestinal parasite with worldwide distribution that inhabits the digestive tract of humans and a large variety of animal hosts [
1‐
3]. In numerous epidemiological surveys, this cosmopolitan enteric parasite was frequently identified as the most common unicellular eukaryote found in human fecal samples [
1,
2,
4]. Indeed, its prevalence may reach 20 % in industrialized countries, including the European population [
5] and 50 % in developing countries [
6]. Recently, the prevalence of
Blastocystis sp. was shown to be 100 % in a cohort of children living in a rural area in Senegal, highlighting the impact of blastocystosis mainly in developing countries with poor healthcare and hygiene [
7]. In this regard, a higher prevalence of this parasite was found among European people with a history of recent travel to tropical countries [
5]. At the morphological level, four major forms of
Blastocystis sp. have been described, including the infective cyst which is able to survive for a long period in feces and environmental sources and is resilient to standard water chlorination, facilitating waterborne transmission of the parasite [
1,
8]. Therefore, the fecal-oral route is considered the main mode of transmission of
Blastocystis sp. through the consumption of food or water contaminated by cysts.
Blastocystosis is usually diagnosed using direct-light microscopy of fecal smears or possibly short-term xenic in vitro culture of stool samples. However, these methods have a low diagnostic sensitivity compared with molecular tools, i.e. PCR assays, and could greatly underestimate the real prevalence of the parasite [
9]. A remarkable genetic diversity has been revealed among
Blastocystis sp. isolates from humans and other animals based on the comparison of small subunit (SSU) rRNA gene sequences. Consequently, seventeen lineages of so-called subtypes (ST1 to ST17) (arguably separate species) have been identified among mammalian and avian isolates [
10], nine of which (ST1 to ST9) are found in humans with varying prevalence [
2,
4]. The other STs (ST10-ST17) are exclusively found in animals [
10]. Based on a recent review including all human samples subtyped thus far across various geographic regions worldwide [
4], approximately 90 % of human isolates belonged to ST1 to ST4, with a predominance of ST3 (around 60 % of these isolates). Even though these four STs were found in different animal hosts, their predominance in the human population is likely explained by large-scale human-to-human transmission [
1,
2]. To our knowledge, ST9 was restricted to humans and until now has been identified in only 3 people from Denmark and Japan [
4]. ST5 to ST8 supposedly of animal origin were rarely found in humans and their presence might be linked to zoonotic transmission. Besides, a higher risk of
Blastocystis sp. infection was found in people with close animal contact, including zoo keepers [
11].
The human health impact of
Blastocystis sp. still remains uncertain because the parasite is frequently found in asymptomatic patients and has been associated with a wide range of non-specific symptoms including diarrhea, abdominal pain, bloating, nausea, and vomiting as well as urticarial lesions [
1‐
3]. However, recent findings using in vitro and in vivo approaches combined with
in silico analysis of genomic data and clinical reports strongly suggested the pathogenic potential of
Blastocystis sp. by identifying putative virulence factors such as cysteine proteases. These proteases are secreted by the parasite and can induce epithelial barrier dysfunction [
1‐
3,
12‐
14]. The proposed models for pathogenesis of
Blastocystis sp. [
13‐
16] mainly involved adhesion of parasites to the intestinal epithelium, apoptosis and degradation of tight junction proteins of intestinal epithelial cells resulting in increased intestinal permeability, degradation of IgA and induction of a pro-inflammatory cytokine response.
Blastocystis sp. was also recently associated with Irritable Bowel Syndrome (IBS) [
16,
17], a multifactorial functional bowel disorder partly explained by dysbiosis [
18].
All these new data provide evidence that the public health burden of
Blastocystis sp. continues to be underestimated, hence the interest in conducting large-scale epidemiological surveys in industrialized countries. In France, very little data were available concerning both the prevalence and ST distribution of
Blastocystis sp. The parasite was previously reported in two French cohorts with a respective prevalence of 3.0 and 6.1 % by direct-light microscopy of fecal smears [
19,
20]. In addition, conflicting ST distributions were observed between two French molecular studies conducted in different geographic areas and both including a limited number of samples [
9,
21]. Therefore, the aim of the present study was to reinforce the picture of
Blastocystis sp. prevalence and molecular ST distribution in Europe by performing the first multi-center survey conducted in France from a large cohort of patients carried out between December 2012 and September 2013.
Discussion
Little data are available in the literature regarding the prevalence of
Blastocystis sp. in France and more generally in European countries. In France, the first two studies reported a prevalence of 3 and 6.1 % in two cohorts of 2,581 and 9,700 patients, respectively, by direct-light microscopy of fecal smears [
19,
20]. More recently, the prevalence of
Blastocystis sp. reached 14.5 % in a single-center study including 186 patients using a molecular assay [
9]. Interestingly, this latter value is roughly similar to the prevalence of 18.1 % reported in the current samples using the same qPCR assay. By comparison, the prevalence reported in a few other neighbouring countries was 24.2 % in the Netherlands (
n = 442) [
5], 23 % in Denmark (
n = 93) [
22], 7.1 % in Italy (
n = 5,351) [
23], 7 % in Spain (
n = 8,313) [
24], and 6.9 and 3.9 % in the United Kingdom (
n = 1,390 and
n = 1,000, respectively) [
25,
26] (Table
3). However, a comparison of the prevalence obtained from these various European studies remains generally uninformative due to the differences in the composition of the cohorts of patients and especially in the diagnostic tools. Indeed, apart from the Dutch and Danish studies, which were conducted using molecular tools and showed a prevalence similar to that of our survey, all other European epidemiological studies were performed using direct-light microscopy or in vitro culture, both methods being shown to be less sensitive than PCR [
9]. The present study confirms this observation, since direct-light microscopy showed only 45.8 % sensitivity compared to the qPCR assay.
Table 3
Prevalence of Blastocystis sp. in European countries
France | Grenoble | 2,581 | Direct-light microscopy | 3.0 % | |
France | Paris | 9,700 | Direct-light microscopy | 6.1 % | |
France | Clermont-Ferrand | 186 | qPCR | 14.5 % | |
France | Multi-center study | 788 | qPCR | 18.1 % | Present study |
The Netherlands | Amsterdam | 442 | PCR | 24.2 % | |
Denmark | Copenhagen | 93 | PCR | 23.0 % | |
Italy | Rome | 5,351 | Direct-light microscopy | 7,1 % | |
Spain | Catalonia | 8,313 | Direct-light microscopy | 7.0 % | |
United Kingdom (Wales) | Aberystwyth | 1,390 | Direct-light microscopy | 6.9 % | |
United Kingdom (Scotland) | Glasgow | 1,000 | In vitro culture and direct-light microscopy | 3.9 % | |
Within the French centers, the prevalence of
Blastocystis sp. ranged from 6.7 to 41.2 %. This variation may be naturally explained by differences in the composition of the respective cohorts from each center, but may also reflect differences in food habits and sources of drinking water in various geographic areas, which are also more or less rural and have different climate conditions. In future studies, the analysis of food and environmental samples in these regions, and especially the control of water sources regarding the presence of
Blastocystis sp., might help identifying potential primary reservoirs of transmission. A key finding of our study was the seasonal impact on the prevalence of
Blastocystis sp., which reached 23.2 % in summer compared to 13.7 % in winter. Interestingly, this seasonal pattern, already described in previous epidemiological surveys [
26‐
29], was observed in 9 of the 10 French centers providing samples during both winter and summer. In France, this difference may be explained by changes in food habits according to the seasons, with an increased consumption of vegetables and fruits, drinks with ice cubes and ice creams in summer. Common water-based recreational activities may also be involved, since human fecal contamination was clearly shown to be correlated with
Blastocystis sp. load in recreational rivers, suggesting a greater risk of infection by the parasite in summer [
28,
29]. Moreover, frequent trips during the summer holidays and stays for instance in densely populated holiday centers could represent other risk factors for infection.
Among our overall population, gender was not identified as a potential risk factor associated with
Blastocystis sp. infection, since the finding of a slightly higher prevalence of the parasite in males (19.5 %) than in females (16.6 %) was not statistically significant. By contrast,
Blastocystis sp. showed a different age-related epidemiological pattern. The mean age was thus significantly lower in
Blastocystis sp.-infected patients (43.0 ± 21.1 years) than in non-carriers of the infection (48.9 ± 21.1 years). In addition, the prevalence of
Blastocystis sp. was significantly higher in subjects aged 15 to 49 years compared to those aged over 50 years (22.2 versus 16.6 %). On the other side, the prevalence of
Blastocystis sp. was also not significantly higher in the age group 0 to 14 years (26.3 %) compared to older age classes, likely due to the too small number of children included in our study. Interestingly, an infection peak was shown between 5and 9 years of age, suggesting that children in this age category might be more at risk for
Blastocystis sp. infection. In this regard, previous studies reported peaking prevalence of the parasite among groups aged under 10 years [
27,
30‐
32]. Such a high rate may be due to inadequate toilet training and hygiene practices of school-children and cross-transmission through close personal contact. In a recent survey conducted in the Netherlands [
5], a significantly higher prevalence of
Blastocystis sp. was reported among patients with a history of recent travel, suggesting that trips to tropical and low-income countries may increase the risk of parasite infection. A similar conclusion was drawn from our study, since travel during the last 12 months was significantly associated with a higher prevalence of
Blastocystis sp. (27.5 versus 14.7 % for non-travellers). Interestingly, the prevalence of the parasite reached 33.3 % in patients reporting at least two travels during the last year in countries at risk. Travellers should therefore follow food and water hygiene recommendations to prevent infection by
Blastocystis sp.
Intestinal parasitic infections are among the leading causes of morbidity and mortality in patients infected with HIV. Consequently, the
Blastocystis sp. detection as a possible pathogenic agent among immunocompromised patients continues to be debated. In this regard, the prevalence of
Blastocystis sp. was previously found to be significantly higher in immunocompromised HIV patients, most presenting with diarrhea, than in HIV-seronegative controls [
33‐
35]. Strikingly,
Blastocystis sp. was the most commonly occurring parasite among the protozoans searched for in HIV-infected individuals [
33,
34,
36,
37], with a prevalence reaching about 70 % in Jakarta, Indonesia [
36]. In addition, a statistically significant association was shown between infection with
Blastocystis sp. and the presence of digestive disorders among severely immunocompromised HIV-positive patients (with CD4+ T-cell counts < 200/μL) [
33]. The prevalence of the parasite was also shown to be negatively correlated with the CD4+ cell count [
36] and was significantly higher in HIV patients without antiretroviral therapy than among HIV-positive patients with treatment [
38]. In immunocompromised patients presenting haematological malignancies,
Blastocystis sp. was more frequently associated with gastrointestinal symptoms than in non-immunocompromised symptomatic patients [
39]. This contrasted with a more recent French survey showing no correlation between digestive symptoms and immune status in patients presenting similar pathology [
9]. All-in-all, immunodepression seems to be a factor of primary importance in the infection and pathogenic role of
Blastocystis sp. However, in the present study, the prevalence of the parasite in immunocompromised subjects was significantly lower than in immunocompetent individuals (12.4 versus 24.2 %, respectively), especially in subgroups of patients receiving immunosuppressive therapy (8.4 %) or with bone marrow transplants (7.7 %). In our opinion, the controlled food diet recommended to these patients for the prevention of potential opportunistic infections along with antibiotic therapy such as metronidazole might have a negative impact on the prevalence of
Blastocystis sp. In addition, a history of travel was shown above to be positively correlated with the prevalence of
Blastocystis sp.. In fact, only 21.5 % of immunocompromised patients reported having travelled during the last 12 months, compared to 35.4 % of immunocompetent individuals.
To clarify the clinical relevance of
Blastocystis sp, numerous studies were published related to the comparison of parasite prevalence between symptomatic and asymptomatic individuals [
1‐
3]. If accumulating epidemiological studies suggested that
Blastocystis sp. was associated with gastrointestinal disorders, numerous reports did not support this association. From our overall population, the prevalence of
Blastocystis sp. was not significantly different between symptomatic and asymptomatic patients, what does not however prejudge the pathogenicity of various isolates. Within the symptomatic group, abdominal pain was reported significantly more frequently in
Blastocystis sp. carriers, in agreement with earlier studies recording abdominal pain as one of the most common symptoms of blastocystosis [
1]. Bloating was also attributed to blastocystosis in various studies [
1]. This symptom was most frequently identified in
Blastocystis sp.-positive subjects of our cohort, but was not significantly associated with parasite infection.
The prevalence of the parasite in patients suffering from chronic bowel disorders was also investigated, since recent studies suggested an association between
Blastocystis sp. and IBS [
2,
16], a functional bowel disorder with a prevalence ranging from 5 to 24 % in industrialized countries [
18]. Based on a systematic review of the literature and a meta-analysis including previous epidemiological studies in IBS cohorts, it was shown that IBS patients had a relative risk of 2.34 of being infected with
Blastocystis sp. when compared to non-IBS subjects [
17]. However, in our study, the prevalence of the parasite was not significantly higher in IBS patients (20 %) compared to non-IBS subjects (18.5 %). Since the diagnosis of IBS is still difficult and requires a specific visit to a gastroenterologist, some patients in our study may not have been diagnosed as positive for IBS, which could impact our results. In parallel, according to various studies, the prevalence of
Blastocystis sp. in IBD patients was reported to be lower or higher than in non-IBD subjects, which probably depends on the type of IBD (mainly Crohn’s disease or ulcerative colitis) [
40,
41]. In our study, the parasite was identified less frequently in IBD subgroups (12 %), but not significantly less than in non-IBD patients (18.4 %). Unfortunately, subgroups analyses from different types of IBD were not performed because of the small size of the IBD cohort.
As part of our study, a total of 141
Blastocystis sp. isolates were subtyped to evaluate the ST distribution within our French cohort. ST3 was the most common ST (43.3 %), followed by ST1 and ST4 (20 %), ST2 (12.8 %), ST6 and ST7 (2.1 %). This distribution is nearly similar to that observed in a majority of geographical areas all over the world, including European countries [
5,
22,
42], with a predominance of ST3, followed by ST1, ST2 or ST4, highlighting large-scale inter-human transmission [
2,
4]. The identification of a few isolates in Lille, Lyon, Nantes, or Clermont-Ferrand belonging to ST6 or ST7 is most likely the result of zoonotic transmission, since both STs are considered avian STs [
1‐
4,
10]. The distribution of some STs in the overall human population showed significant geographical variations, especially in relation to the ST4 [
2,
4]. Our data thus confirmed that ST4 is commonly found in Europe [
5,
22,
42] and especially in France [
9], and is much less frequently detected or absent in Africa, America and Asia. This observation might perhaps be explained by the recently proposed emergence of ST4 in the human population in Europe [
2]. The ST distribution was also variable between different French centers, although ST3 was predominant in 8 of the 11 centers. In two previous studies conducted in France, ST3 was the most frequent ST in Lille [
21], whereas ST4 showed a higher prevalence in Clermont-Ferrand [
9], in agreement with our survey. These patterns in ST distribution, as well as in prevalence of the parasite between centers, suggest that reservoirs and/or sources of contamination may differ from any geographical area of France to another. Until now, and for different reasons, the epidemiological data remain contradictory regarding the correlation between ST and the pathogenesis of
Blastocystis sp. [
1,
21]. In this regard, our study failed to provide any evidence for ST association with specific symptoms status.
Acknowledgements
The authors would like to thank all those who participated in the study and staff at all participating centers: Pr P-Y Hatron, Pr E Hachulla, Pr F Gottrand, Dr F Dubos, Pr I Yakoub Agha and Dr V Coiteux (CHRU of Lille) and Christine Bureau (CHRU of Nantes).